| NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. | |
| | |
MedLine Citation:
|
PMID: 19920806 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of ursodeoxycholic acid (UDCA), which showed selective vasodilatory effect on intrahepatic circulation in animal models of cirrhosis. This study was aimed at testing the efficacy and tolerability of this compound in patients with cirrhosis and portal hypertension. METHODS: This was a single-center, phase-2a, randomized (4:1), double-blind, parallel-group, dose-escalating study. Patients received progressive oral doses of NCX-1000 or placebo up to 2 g t.i.d. or maximum tolerated doses for 16 days. Efficacy on fasting and postprandial hepatic venous pressure gradient (HVPG) at baseline and after treatment was assessed. Hepatic blood flow (HBF) and arterial blood pressure were also measured. RESULTS: Eleven patients (nine NCX-1000 and two placebo) were enrolled and completed the trial. After NCX-1000 treatment, HVPG did not change (16.7+/-3.8 vs. 17.1+/-3.8 mm Hg; P=0.596), and HBF decreased significantly (904+/-310 vs. 1,129+/-506 ml/min; P=0.043). The postprandial increase in portal pressure and HBF was not modified by NCX-1000. There was no significant effect on diastolic blood pressure, but systolic blood pressure was reduced by the treatment in a dose-dependent manner (121+/-11 mm Hg after NCX-1000 vs. 136+/-7 mm Hg at baseline; P=0.003). Seven non-serious adverse events were experienced by four patients (one on placebo). CONCLUSIONS: In patients with cirrhosis and portal hypertension, NCX-1000 administration was safe, but it was not able to reduce portal pressure. A significant reduction of systolic blood pressure and HBF was observed in the treatment arm, suggesting that the drug had systemic effects and lacked selective release of NO at the intrahepatic circulation. |
| | |
Authors:
|
Annalisa Berzigotti; Pau Bellot; Andrea De Gottardi; Juan Carlos Garcia-Pagan; Caroline Gagnon; Jean Sp?nard; Jaime Bosch |
Related Documents
:
|
2942316 - Endoscopic measurements of intravascular pressure and flow in blood vessels of gastroin... 7735986 - Systemic and portal prostacyclin and thromboxane response to hemorrhage in portal hyper... 2308476 - Effect of parathyroid hormone on portal pressure in portal hypertensive rats. 9649466 - Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in th... 12818956 - Arx-derived auditory evoked potential index and bispectral index during the induction o... 10075386 - Effects of insufficient sleep on blood pressure in hypertensive patients: a 24-h study. |
Publication Detail:
|
Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2009-11-17 |
Journal Detail:
|
Title: The American journal of gastroenterology Volume: 105 ISSN: 1572-0241 ISO Abbreviation: Am. J. Gastroenterol. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-06 Completed Date: 2010-06-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0421030 Medline TA: Am J Gastroenterol Country: United States |
Other Details:
|
Languages: eng Pagination: 1094-101 Citation Subset: IM |
Affiliation:
|
Hepatic Hemodynamics Laboratory, Hospital Cl?nic-IDIBAPS, University of Barcelona, Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Aged Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Humans Hypertension, Portal / diagnosis, drug therapy*, etiology Liver Circulation / drug effects Liver Cirrhosis / complications, diagnosis, drug therapy* Male Manometry Maximum Tolerated Dose Middle Aged Nitrates / administration & dosage*, adverse effects Nitric Oxide Donors / administration & dosage*, adverse effects Portal Pressure / drug effects* Reference Values Risk Assessment Severity of Illness Index Treatment Failure Ursodeoxycholic Acid / administration & dosage, adverse effects, analogs & derivatives* |
| Chemical | |
Reg. No./Substance:
|
0/2-methyl-3-(2-((4-nitrooxybutyloxy)carbonyl)vinyl)phenyl ursodeoxycholic acid ester; 0/Nitrates; 0/Nitric Oxide Donors; 128-13-2/Ursodeoxycholic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pretranscriptional regulation of Tgf-beta1 by PI polyamide prevents scarring and accelerates wound h...
Next Document: Errors in the Conduct of Systematic Reviews of Pharmacological Interventions for Irritable Bowel Syn...